# Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

> **NCT00006488** · PHASE1 · COMPLETED · sponsor: **National Center for Research Resources (NCRR)**

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** recombinant-methionyl human glial cell line-derived neurotrophic factor

## Key facts

- **NCT ID:** NCT00006488
- **Lead sponsor:** National Center for Research Resources (NCRR)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006488, "Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00006488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*